Seminars in Nephrology
Volume 29, Issue 6 , Pages 594-603 , November 2009

Identifying Advanced Glycation End Products as a Major Source of Oxidants in Aging: Implications for the Management and/or Prevention of Reduced Renal Function in Elderly Persons

  • Helen Vlassara, MD

      Affiliations

    • Division of Diabetes and Aging, Department of Geriatrics, Mount Sinai School of Medicine, New York, NY
    • Corresponding Author InformationAddress reprint requests to Helen Vlassara, MD, Mount Sinai School of Medicine, Box 1640, One Gustave Levy Pl, New York, NY 10029
    • ,
  • Jaime Uribarri, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY
    • ,
  • Luigi Ferrucci, MD

      Affiliations

    • Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD
    • ,
  • Weijing Cai, MD

      Affiliations

    • Division of Diabetes and Aging, Department of Geriatrics, Mount Sinai School of Medicine, New York, NY
    • ,
  • Massimo Torreggiani, MD

      Affiliations

    • Division of Diabetes and Aging, Department of Geriatrics, Mount Sinai School of Medicine, New York, NY
    • Unit of Nephrology, Dialysis and Transplantation, University of Pavia, Pavia, Italy
    • ,
  • James B. Post, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY
    • ,
  • Feng Zheng, MD, PhD

      Affiliations

    • Division of Diabetes and Aging, Department of Geriatrics, Mount Sinai School of Medicine, New York, NY
    • ,
  • Gary E. Striker, MD

      Affiliations

    • Division of Diabetes and Aging, Department of Geriatrics, Mount Sinai School of Medicine, New York, NY
    • Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY

References 

  1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  2. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008;74:101–107
  3. Finkel TH. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239–247
  4. Abbatecola AM, Ferrucci L, Grella R, Bandinelli S, Bonafe M, Barbieri M, et al. Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc. 2004;52:399–404
  5. Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab. 2003;88:2019–2025
  6. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–512
  7. Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP, et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 2002;50:638–644
  8. Stadtman ER. Role of oxidant species in aging. Curr Med Chem. 2004;11:1105–1112
  9. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–495
  10. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol. 2005;25:815–820
  11. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Pinero G, Avezum A, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003;89:1003–1008
  12. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94:6474–6479
  13. Linden E, Cai W, He JC, Xue C, Li Z, Winston J, et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol. 2008;3:691–698
  14. Fried LF, Lee JS, Shlipak M, Chertow GM, Green C, Ding J, et al. Chronic kidney disease and functional limitation in older people: health, aging and body composition study. J Am Geriatr Soc. 2006;54:750–756
  15. Baylis C, Corman B. The aging kidney: insights from experimental studies. J Am Soc Nephrol. 1998;9:699–709
  16. Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, Misek DE, et al. Podocyte hypertrophy, “adaptation,” and “decompensation” associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol. 2005;16:2953–2966
  17. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1–9
  18. Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, Hotta N. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun. 1996;228:539–543
  19. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62:427–433
  20. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596–15601
  21. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep. 2007;7:235–241
  22. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med. 2000;28:1708–1716
  23. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993;90:6434–6438
  24. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci. 2005;62:1671–1681
  25. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification—a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol. 1996;27:565–573
  26. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci. 2005;1043:452–460
  27. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54:3103–3111
  28. Cai W, He JC, Zhu L, Chen X, Wallenstein S, Striker GE, et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol. 2007;170:1893–1902
  29. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009–1016
  30. Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A. 1996;93:3902–3907
  31. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A. 1998;95:4630–4634
  32. Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, Fisher EA, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2003;168:213–220
  33. Himmelfarb J, McMonagle E. Manifestations of oxidant stress in uremia. Blood Purif. 2001;19:200–205
  34. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis. 2004;43:690–695
  35. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A. 1994;91:8807–8811
  36. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A. 2004;101:11767–11772
  37. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev. 2001;17:436–443
  38. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949–955
  39. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products (Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions). Arterioscler Thromb. 1994;14:1521–1528
  40. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99–111
  41. He CJ, Koschinsky T, Buenting C, Vlassara H. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med. 2001;7:159–168
  42. Zheng F, Plati AR, Potier M, Schulman Y, Berho M, Banerjee A, et al. Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol. 2003;162:1339–1348
  43. Zheng F, Cheng QL, Plati AR, Ye SQ, Berho M, Banerjee A, et al. The glomerulosclerosis of aging in females: contribution of the proinflammatory mesangial cell phenotype to macrophage infiltration. Am J Pathol. 2004;165:1339–1348
  44. Zheng F, Plati AR, Cheng Q, Bertho M, Banerjee A, Potier M, et al. Glomerular aging in females is a multi-stage reversible process mediated by phenotypic changes in progenitors. Am J Pathol. 2005;162:355–363
  45. Cornacchia F, Fornoni A, Plati AR, Thomas A, Wang Y, Inverardi L, et al. Glomerulosclerosis is transmitted by bone marrow-derived mesangial cell progenitors. J Clin Invest. 2001;108:1649–1656
  46. Zheng F, Cornacchia F, Schulman I, Banerjee A, Cheng QL, Potier M, et al. Development of albuminuria and glomerular lesions in normoglycemic B6 recipients of db/db mice bone marrow: the role of mesangial cell progenitors. Diabetes. 2004;53:2420–2427
  47. Tack I, Elliot SJ, Potier M, Rivera A, Striker GE, Striker LJ. Autocrine activation of the IGF-I signaling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes. 2002;51:182–188
  48. Fornoni A, Lenz O, Striker LJ, Striker GE. Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice. Diabetes. 2003;52:2594–2602
  49. Fornoni A, Striker LJ, Zheng F, Striker GE. Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes. 2002;51:499–505
  50. Zheng F, Fornoni A, Elliot SJ, Guan Y, Breyer MD, Striker LJ, et al. Upregulation of type 1 collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol. 2002;282:F639–F648
  51. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int. 2006;70:507–514
  52. Park C, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006;69:1511–1517
  53. Potier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am J Pathol. 2002;160:1877–1885
  54. Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol. 2003;162:1441–1448
  55. Karl M, Berho M, Pignac-Kobinger J, Striker GE, Elliot SJ. Differential effects of continuous and intermittent 17beta-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis: modulation of the mesangial cell phenotype in vivo. Am J Pathol. 2006;169:351–361
  56. Potier M, Karl M, Elliot SJ, Striker GE, Striker LJ. Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice. Am J Physiol Endocrinol Metab. 2003;285:E1237–E1245
  57. Bobadilla NA, Tack I, Tapia E, Sanchez-Lozada LG, Santamaria J, Jimenez F, et al. Pentosan polysulfate prevents glomerular hypertension and structural injury despite persisting hypertension in 5/6 nephrectomy rats. J Am Soc Nephrol. 2001;12:2080–2087
  58. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol. 2008;173:327–336
  59. Vlassara H. Protein glycation in the kidney: role in diabetes and aging. Kidney Int. 1996;49:1795–1804
  60. Ruggiero C, Metter EJ, Melenovsky V, Cherubini A, Najjar SS, Ble A, et al. High basal metabolic rate is a risk factor for mortality: the Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci. 2008;63:698–706
  61. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–285
  62. Dols LF, Weimar W, Ijzermans JN. Long-term consequences of kidney donation. N Engl J Med. 2009;360:2371–2372
  63. Pizzarelli F, Lauretani F, Bandinelli S, Windham GB, Corsi AM, Giannelli SV, et al. Predictivity of survival according to different equations for estimating renal function in community-dwelling elderly subjects. Nephrol Dial Transplant. 2009;24:1197–1205
  64. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Zhu L, et al. Protection against loss of innate defenses in adulthood by low AGE intake; role of a new anti-inflammatory AGE-receptor-1. Endocrinology. 2009;In press
  65. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728–731

PII: S0270-9295(09)00155-7

doi: 10.1016/j.semnephrol.2009.07.013

Seminars in Nephrology
Volume 29, Issue 6 , Pages 594-603 , November 2009

Article Tools

* Image Usage & Resolution